Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/RB0 stock hub

FRA/RB0 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/RB0is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

462.7M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/RB0FRA/RB0

—

Loading chart…

In the news

Latest news · FRA/RB0

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-107

P25 n/aP50 n/aP75 n/a

ROIC-111.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/RB0 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

163

Groups with data

Currency

USD

Showing 163 of 163 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	371
Employees Change	18%
Employees Change Percent	5.1
Enterprise value	EUR 479.4M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 462.7M
Price	EUR 8.81
Price currency	EUR
Rev Per Employee	391,279.25x
Sic	2836
Symbol	fra/RB0
Website	https://www.regenxbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-35.69%
EV Earnings	-2.9x
EV/FCF	-4.45x
EV/Sales	3.31x
FCF yield	-23.26%
P/B ratio	5.29x
P/S ratio	3.19x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-94.58%
EBITDA Margin	-85.42%
Gross margin	-45.86%
Gross Profit	EUR -66.6M
Net Income	EUR -165.1M
Pretax Margin	-113.75%
Profit Margin	-113.75%
Profit Per Employee	EUR -445,083
ROA	-21.93
Roa5y	-15.73
ROCE	-48.13
ROE	-107
Roe5y	-54.31
ROIC	-111.7
Roic5y	-65.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	0.27%
Cagr1y	27.64%
Cagr3y	-21.05%
Cagr5y	-20.96%
Revenue Growth	104.54x
Revenue Growth Q	43.01x
Revenue Growth3 Y	14.78x
Revenue Growth5 Y	1.97x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.37
Assets	EUR 385.8M
Cash	EUR 196M
Current Assets	EUR 238.5M
Current Liabilities	EUR 100.1M
Debt	EUR 221.9M
Debt Equity	EUR 2.54
Debt FCF	EUR -2.06
Equity	EUR 87.5M
Interest Coverage	-3.58
Liabilities	EUR 298.3M
Long Term Assets	EUR 147.3M
Long Term Liabilities	EUR 198.2M
Net Cash	EUR -16.7M
Net Cash By Market Cap	EUR -3.62
Net Debt Equity	EUR 0.19
Tangible Book Value	EUR 87.5M
Tangible Book Value Per Share	EUR 1.72

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.38
Net Working Capital	EUR -16.2M
Quick ratio	2.27
Working Capital	EUR 139M
Working Capital Turnover	EUR 0.86

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.17%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	2.74%
1Y total return	27.62%
200-day SMA	8.94
3Y total return	-50.8%
50-day SMA	7.58
50-day SMA vs 200-day SMA	50under200
5Y total return	-69.16%
All Time High	72.49
All Time High Change	-87.85%
All Time High Date	2018-07-10
All Time Low	4.68
All Time Low Change	88.16%
All Time Low Date	2025-04-09
ATR	0.29
Ch YTD	-26.62
High	8.81
High52	13.6
High52 Date	2026-01-14
High52ch	-35.25%
Low	8.81
Low52	6.3
Low52 Date	2025-05-09
Low52ch	39.78%
Ma50ch	16.22%
Price vs 200-day SMA	-1.47%
RSI	64.32
RSI Monthly	45.76
RSI Weekly	50.71
Sharpe ratio	0.77x
Sortino ratio	1.24
Total Return	-4.17%
Tr YTD	-26.62
Tr1m	18.27%
Tr1w	14.45%
Tr3m	2.99%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -137.3M
Operating margin	-94.58

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	43,001,937%
Shares Insiders	8.23%
Shares Institutions	71.67%
Shares Qo Q	0.12%
Shares Yo Y	4.17%
Short Ratio	8.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -137.1M
Average Volume	30.3x
Bv Per Share	1.72
CAPEX	EUR -2.1M
Ch10y	2.74
Ch1m	18.27
Ch1w	14.45
Ch1y	27.62
Ch3m	2.99
Ch3y	-50.8
Ch5y	-69.16
Ch6m	-8.75
Change	2.59%
Change From Open	-0.05
Close	8.58
Days Gap	2.68
Depreciation Amortization	13,240,926.6
Earnings Date	2026-05-14
EBIT	EUR -137.3M
EBITDA	EUR -124M
EPS	EUR -3.2
F Score	3
FCF	EUR -107.6M
FCF EV Yield	-22.45x
Financing CF	99,453,861
Fiscal Year End	December
Founded	2,008
Investing CF	-13,514,776
Is Primary Listing	0
Last Earnings Date	2026-02-24
Last Report Date	2025-12-31
Ma150	9.4
Ma150ch	-6.35%
Ma20	7.75
Ma20ch	13.66%
Net CF	-19,640,202
Next Earnings Date	2026-05-14
Open	8.81
Ppne	128,899,551.6
Price Date	2026-05-08
Ptbv Ratio	5.29
Relative Volume	2.96x
Revenue	145,164,600x
SBC By Revenue	20.28x
Share Based Comp	29,437,307
Tr6m	-8.75%
Volume	0
Z Score	-3.04

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/RB0 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/RB0 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/RB0?

Insider, institutional, and short-interest positioning.

Institutional ownership

+71.7%

Share of float held by funds and institutions

Insider ownership

+8.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/RB0 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

64.3

Neutral momentum band

Price vs 200-day MA

-1.5%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.77

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/RB0

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/RB0 stock rating?

fra/RB0 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/RB0 analysis?

The full report lives at /stocks/fra/RB0/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/RB0?

The latest report frames fra/RB0 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/RB0 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.